Report Description

Forecast Period


Market Size (2023)

USD 284.13 million

Market Size (2029)

USD 394.42 million

CAGR (2024-2029)


Fastest Growing Segment


Largest Market



Market Overview

United States Ovarian Cancer Diagnostics Market was valued at USD 284.13 million in 2023 and is anticipated to project impressive growth in the forecast period with a CAGR of 5.79% through 2029. The United States Ovarian Cancer Diagnostics Market plays a crucial role in the nation's healthcare sector by focusing on the early detection and diagnosis of ovarian cancer, a leading cause of cancer-related deaths among women. This market is dynamic and continuously evolving, offering a range of diagnostic tools and technologies to improve early intervention and patient outcomes. Ovarian cancer is notoriously challenging to detect early due to vague symptoms, underscoring the importance of robust diagnostics. Key components of the U.S. ovarian cancer diagnostics market include advanced imaging techniques like ultrasound, magnetic resonance imaging (MRI), and computed tomography (CT) scans, which help identify ovarian tumors and assess their characteristics. Blood-based biomarker tests such as CA-125 and HE4 are vital for monitoring disease progression and guiding treatment decisions. In recent years, there's been a significant shift towards precision medicine, with molecular diagnostics gaining importance. Genetic testing and next-generation sequencing techniques are now standard for identifying specific genetic mutations linked to ovarian cancer, enabling personalized treatment and targeted therapies. Liquid biopsies are emerging as a non-invasive method for detecting genetic alterations and monitoring disease progression, promising advancements in early detection and disease management.

The U.S. ovarian cancer diagnostics market features a competitive landscape, with diagnostic companies, healthcare institutions, and research organizations actively contributing to advancements in early detection and diagnostics. Collaborative efforts between academia and industry have led to innovative diagnostic tools and cutting-edge research, ensuring that ovarian cancer patients receive optimal care.

Key Market Drivers

Growing Incidence and Prevalence of Ovarian Cancer

The expansion of the United States Ovarian Cancer Diagnostics Market is significantly driven by the increasing incidence and prevalence of ovarian cancer. Known as the "silent killer," ovarian cancer contributes significantly to cancer-related deaths among women, prompting a heightened demand for early and efficient diagnostic tools. Factors such as an aging population and the growing prevalence of risk factors like obesity have fueled the steady rise in ovarian cancer incidence. With age being a prominent risk factor, timely diagnosis becomes crucial in reducing mortality rates. This demographic shift has led to a greater awareness of the importance of early detection. Advancements in understanding risk factors and genetic predispositions to ovarian cancer highlight the necessity for heightened vigilance in diagnostic practices. Individuals with a family history of ovarian or breast cancer face increased susceptibility, emphasizing the importance of regular screenings and diagnostic tests. The genetic aspect of ovarian cancer is driving a shift towards personalized medicine, where genetic testing identifies high-risk individuals who may benefit from more intensive surveillance or preventative measures. Lifestyle factors and environmental exposures also contribute to the overall prevalence of ovarian cancer in the US. In response, advocacy groups, healthcare organizations, and government agencies are intensifying efforts to raise awareness and promote early detection. Events like Ovarian Cancer Awareness Month in September serve as crucial platforms for community engagement and education on available screening options, signs, and symptoms.

Advancements in Diagnostic Technologies

Progress in diagnostic technologies is a key driver fueling the growth of the United States Ovarian Cancer Diagnostics Market. Ovarian cancer, notorious for its elusive nature, benefits greatly from ongoing advancements that enhance early detection, diagnostic accuracy, and precision. While traditional methods like transvaginal ultrasound and the CA-125 blood test have been instrumental, modern diagnostic tools expand the horizons. Molecular diagnostics and genetic testing stand out as game-changers, pinpointing specific genetic mutations linked to ovarian cancer. This personalized approach tailors treatment plans based on an individual's genetic profile, thus improving outcomes. Liquid biopsies represent another groundbreaking development, offering a minimally invasive means of detecting cancer-related DNA or proteins in the bloodstream. This method holds promise for early detection and monitoring, making diagnosis more accessible and comfortable for patients. The imaging technologies, such as MRI and CT scans, have seen significant advancements, enabling the early detection of ovarian tumors, even in asymptomatic stages. These refined imaging methods provide clearer insights, enhancing diagnostic accuracy and efficiency.

Increasing Awareness and Screening Initiatives

Increasing awareness and screening efforts are key drivers propelling the growth of the United States Ovarian Cancer Diagnostics Market. Ovarian cancer's silent and insidious nature presents a significant challenge, but concerted awareness-raising endeavors and screening campaigns are making a notable impact. Various stakeholders, including advocacy groups, healthcare organizations, and governmental agencies, have spearheaded awareness campaigns, educational initiatives, and community engagement activities. These efforts aim to inform the public about the risks, symptoms, and importance of early detection of ovarian cancer. September, designated as Ovarian Cancer Awareness Month, marks a period of intensified awareness campaigns. Targeted awareness efforts also extend to high-risk groups, such as individuals with a family history of ovarian or breast cancer or those carrying specific genetic mutations. Increased awareness within these cohorts prompts proactive screening measures from a younger age, driving demand for ovarian cancer diagnostics. 

Healthcare providers actively promote screenings, while patients are becoming more proactive in managing their health. This growing awareness of early diagnosis's significance fuels the demand for advanced and accessible diagnostic tools. Government support and funding, notably from agencies like the National Cancer Institute (NCI) and the Centers for Disease Control and Prevention (CDC), play a crucial role in promoting awareness and screening initiatives. Research grants and resources provided by federal agencies facilitate these efforts, incentivizing the development of innovative diagnostic technologies and reducing market entry barriers.

Download Free Sample Report

Key Market Challenges

Asymptomatic Nature of Ovarian Cancer

The asymptomatic nature of ovarian cancer is a significant hurdle hindering the United States Ovarian Cancer Diagnostics Market. Often referred to as the "silent killer," ovarian cancer is notorious for its lack of early warning signs or specific symptoms, making it difficult to detect until it reaches advanced, and frequently incurable, stages. This silent progression of the disease places a substantial burden on the healthcare system and poses a considerable challenge for patients and healthcare providers.

The absence of noticeable symptoms in the early stages of ovarian cancer leads to delayed diagnosis. Patients typically seek medical attention only when they experience symptoms associated with advanced stages, such as abdominal pain, bloating, or difficulty eating. At this point, the disease is more likely to have already spread beyond the ovaries, significantly reducing the chances of successful treatment.

The lack of specific symptoms or signs that would prompt routine screening further compounds the problem. Unlike breast or cervical cancer, for which effective screening methods are widely available, no routine and highly effective ovarian cancer screening test currently exists. The absence of a reliable and accessible screening tool means that many cases of ovarian cancer remain undiagnosed until it is too late for effective treatment.

High Cost of Diagnostic Tests

The high cost of diagnostic tests is a substantial impediment to the growth and accessibility of the United States Ovarian Cancer Diagnostics Market. While advances in diagnostic technologies have the potential to revolutionize the early detection of ovarian cancer, the financial burden associated with these tests creates significant barriers for both patients and healthcare providers.One of the primary diagnostic methods for ovarian cancer is genetic testing, which examines specific genetic mutations associated with the disease. Genetic profiling is essential for personalizing treatment plans and assessing the risk of recurrence. However, these tests often come with a substantial price tag, making them less accessible to many patients.

Imaging technologies, such as magnetic resonance imaging (MRI) and computed tomography (CT) scans, are also vital for diagnosing ovarian cancer. These advanced imaging methods provide detailed information about the size and characteristics of ovarian tumors, but the cost of these procedures can be exorbitant. he financial impact of these diagnostic tests can deter both patients and healthcare providers from pursuing early detection and genetic profiling. This results in missed opportunities for timely intervention and personalized treatment plans. The high cost of diagnostic tests places a considerable burden on patients, even those with insurance coverage. Copayments, deductibles, and out-of-pocket expenses can be substantial, especially when multiple diagnostic tests are required. In some cases, patients may face financial hardship or be forced to make difficult choices between paying for diagnostics and other essential needs.

Key Market Trends

Advancements in Molecular Diagnostics

Advancements in molecular diagnostics have emerged as a pivotal driver behind the remarkable growth of the United States Ovarian Cancer Diagnostics Market. This trend represents a significant leap forward in the field of cancer diagnostics, particularly for ovarian cancer, where early detection is critical. Molecular diagnostics encompass genetic testing and molecular profiling, which enable healthcare providers to identify specific genetic mutations associated with the disease, paving the way for highly personalized and precise treatment plans. The use of genetic testing in ovarian cancer diagnostics has revolutionized the approach to the disease. These advancements empower healthcare professionals to tailor therapies to the unique genetic profiles of individual patients. This not only enhances the efficacy of treatment but also minimizes the risk of adverse effects. In the context of ovarian cancer, which is characterized by multiple subtypes, understanding the specific genetic mutations driving the disease is vital for developing targeted therapies.

The genetic testing plays a key role in assessing the risk of ovarian cancer in high-risk individuals, such as those with a family history of the disease or specific genetic mutations known to increase susceptibility. These individuals can benefit from earlier and more vigilant surveillance, potentially leading to early detection and intervention. The advancements in molecular diagnostics also hold promise for uncovering new biomarkers and genetic targets for drug development, further accelerating progress in ovarian cancer research. The ongoing exploration of novel biomarkers associated with early-stage ovarian cancer is a testament to the transformative power of molecular diagnostics.

Liquid Biopsies for Early Detection

The adoption of liquid biopsies for early detection is making significant strides in boosting the United States Ovarian Cancer Diagnostics Market. Liquid biopsies, a non-invasive diagnostic approach, have emerged as a revolutionary tool in the early detection and monitoring of ovarian cancer. This innovative technology involves the analysis of blood or other bodily fluids to detect cancer-related DNA or proteins, offering a more accessible and comfortable alternative to traditional diagnostic methods.

One of the primary advantages of liquid biopsies is their potential to identify genetic alterations associated with ovarian cancer at an earlier and more treatable stage. Ovarian cancer, often referred to as the "silent killer," is notorious for its asymptomatic early stages, which typically lead to delayed diagnosis. Liquid biopsies, by contrast, can reveal the presence of specific genetic mutations linked to the disease, even before symptoms manifest. This enables physicians to initiate treatment at an earlier, more curable stage, significantly improving patient outcomes.

The liquid biopsies are valuable tools for monitoring disease progression and assessing the effectiveness of treatments. They provide real-time insights into the genetic alterations of the cancer, allowing for adjustments to treatment plans when necessary. This adaptability is crucial in optimizing patient care and enhancing overall survival rates. The growth of liquid biopsies in the ovarian cancer diagnostics market is also driven by their non-invasive nature, which reduces patient discomfort and risk. Unlike traditional diagnostic methods, such as transvaginal ultrasounds or surgical biopsies, liquid biopsies involve a simple blood draw, making them more acceptable to patients and facilitating routine screening for at-risk individuals.

Segmental Insights

Diagnosis Type Insights

Based on the Diagnosis Type, Imaging emerged as the dominant segment in the United States market for United States Ovarian Cancer Diagnostics Market in 2023Imaging modalities like transvaginal ultrasounds, magnetic resonance imaging (MRI), and computed tomography (CT) scans offer a non-invasive approach, eliminating the need for surgery or tissue sampling, such as biopsies. This non-invasive nature is particularly beneficial for patients, minimizing discomfort and lowering the risk of complications. Imaging services are widely accessible across healthcare facilities throughout the United States, including hospitals, clinics, and specialized imaging centers. This ensures broad availability and prompt diagnosis for patients seeking diagnostic evaluations.

End Use Insights

Based on the End Use, Cancer Diagnostic Centers emerged as the dominant segment in the United States market for United States Ovarian Cancer Diagnostics Market in 2023. Cancer diagnostic facilities specialize in identifying and diagnosing various cancers, including ovarian cancer, employing teams of oncologists, radiologists, pathologists, and other specialists well-versed in cancer diagnostics. Their specialized knowledge and experience are vital for ensuring precise and dependable ovarian cancer diagnoses. The focused expertise found in these centers enables swift and thorough evaluations of individuals displaying cancer symptoms or risk factors. Early detection is paramount for enhancing patient prognoses, particularly in ovarian cancer cases, where timely identification can substantially influence survival rates.

Download Free Sample Report

Regional Insights

Mid-West emerged as the dominant player in the United States Ovarian Cancer Diagnostics Market in 2023, holding the largest market share. The Midwest region boasts a wealth of renowned healthcare facilities, including major cancer centers, research institutions, and hospitals with specialized oncology departments. These institutions are at the forefront of ovarian cancer diagnostics, offering state-of-the-art equipment and expertise. The Midwest is home to some of the country's most prestigious research institutions and universities. The collaborative efforts of these institutions have led to groundbreaking innovations in ovarian cancer diagnostics, as well as the development of new diagnostic technologies.

Recent Developments

  • In June 2019, Foundation Medicine announced that its FoundationOne CDx, a comprehensive genomic profiling test, received FDA approval. This approval positions it as a companion diagnostic for LYNPARZA (Olaparib) when utilized in first-line maintenance therapy for metastatic ovarian cancer with BRCA mutations, both germline and somatic, showcasing the test's ability to detect these genetic abnormalities.
  • In November 2022, Roche received FDA approval for the VENTANA FOLR1 (FOLR1-2.1) RxDx Assay, making it the first IHC-based companion diagnostic authorized to assess eligibility for ELAHERE treatment in ovarian cancer patients.

Key Market Players

  • Abbott Laboratories Inc.
  • F. Hoffmann-La Roche Ltd.
  • GlaxoSmithKline plc
  • Johnson & Johnson
  • AstraZeneca plc
  • Siemens Healthcare GmbH
  • Quest Diagnostics Incorporated
  • Thermo Fisher Scientific Inc
  • Bio-Rad Technologies Inc
  • Eli Lily and Company


 By Diagnosis Type

By Cancer Type

By End Use

By Region

  • Imaging
  • Blood Test
  • Biopsy
  • Others
  • Epithelial Tumor
  • Germ Cell Tumor
  • Stromal Cell Tumor
  • Others
  • Hospital Laboratories
  • Cancer Diagnostic Centers
  • Research Institutes
  • Others
  • North-East
  • Mid-west
  • West
  • South


Report Scope:

In this report, the United States Ovarian Cancer Diagnostics Market   has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

  • United States Ovarian Cancer Diagnostics Market, By Diagnosis Type:

o   Imaging

o   Blood Test

o   Biopsy

o   Others

  • United States Ovarian Cancer Diagnostics Market, By Cancer Type:

o   Epithelial Tumor

o   Germ Cell Tumor

o   Stromal Cell Tumor

o   Others

  • United States Ovarian Cancer Diagnostics Market, By End Use:

o   Hospital Laboratories

o   Cancer Diagnostic Centers

o   Research Institutes

o   Others

  • United States Ovarian Cancer Diagnostics Market, By Region:

o   North-East

o   Mid-west

o   West

o   South

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the United States Ovarian Cancer Diagnostics Market.

Available Customizations:

United States Ovarian Cancer Diagnostics Market report with the given market data, Tech Sci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

United States Ovarian Cancer Diagnostics Market   is an upcoming report to be released soon. If you wish an early delivery of this report or want to confirm the date of release, please contact us at [email protected]

Table of content

1.    Product Overview

1.1.  Market Definition

1.2.  Scope of the Market

1.2.1.    Markets Covered

1.2.2.    Years Considered for Study

1.2.3.    Key Market Segmentations

2.    Research Methodology

2.1.  Objective of the Study

2.2.  Baseline Methodology

2.3.  Key Industry Partners

2.4.  Major Association and Secondary Sources

2.5.  Forecasting Methodology

2.6.  Data Triangulation & Validation

2.7.  Assumptions and Limitations

3.    Executive Summary

3.1.  Overview of the Market

3.2.  Overview of Key Market Segmentations

3.3.  Overview of Key Market Players

3.4.  Overview of Key Regions/Countries

3.5.  Overview of Market Drivers, Challenges, Trends

4.    United States Ovarian Cancer Diagnostics Market Outlook

4.1.  Market Size & Forecast

4.1.1.    By Value

4.2.  Market Share & Forecast

4.2.1.    By Diagnosis Type (Imaging, Blood Test, Biopsy, Others)

4.2.2.    By Cancer Type (Epithelial Tumor, Germ Cell Tumor, Stromal Cell Tumor, Others)

4.2.3.    By End Use (Hospital Laboratories, Cancer Diagnostic Centers, Research Institutes, Others)

4.2.4.    By Region

4.2.5.    By Company (2023)

4.3.  Market Map

4.3.1.    By Diagnosis Type  

4.3.2.    By Cancer Type

4.3.3.    By End Use

4.3.4.    By Region

5.    North-East Ovarian Cancer Diagnostics Market Outlook

5.1.  Market Size & Forecast

5.1.1.    By Value

5.2.  Market Share & Forecast

5.2.1.    By Diagnosis Type  

5.2.2.    By Cancer Type

5.2.3.    By End Use

6.    Mid-west Ovarian Cancer Diagnostics Market Outlook

6.1.  Market Size & Forecast

6.1.1.    By Value

6.2.  Market Share & Forecast

6.2.1.    By Diagnosis Type  

6.2.2.    By Cancer Type

6.2.3.    By End Use

7.    West Ovarian Cancer Diagnostics Market Outlook

7.1.  Market Size & Forecast

7.1.1.    By Value

7.2.  Market Share & Forecast

7.2.1.    By Diagnosis Type  

7.2.2.    By Cancer Type

7.2.3.    By End Use

8.    South Ovarian Cancer Diagnostics Market Outlook

8.1.  Market Size & Forecast

8.1.1.    By Value

8.2.  Market Share & Forecast

8.2.1.    By Diagnosis Type  

8.2.2.    By Cancer Type

8.2.3.    By End Use

9.    Market Dynamics

9.1.  Drivers

9.2.  Challenges

10. Market Trends & Developments

10.1.             Recent Developments

10.2.             Product Launches

10.3.             Mergers & Acquisitions

11. United States Ovarian Cancer Diagnostics Market: SWOT Analysis

12. Porter’s Five Forces Analysis

12.1.             Competition in the Industry

12.2.             Potential of New Entrants

12.3.             Power of Suppliers

12.4.             Power of Customers

12.5.             Threat of Substitute Product

13. Competitive Landscape

13.1.        Abbott Laboratories Inc.

13.1.1.         Business Overview

13.1.2.          Company Snapshot

13.1.3.          Products & Services

13.1.4.          Financials (In case of listed)

13.1.5.          Recent Developments

13.1.6.          SWOT Analysis

13.2.   F. Hoffmann-La Roche Ltd.

13.3.   GlaxoSmithKline plc

13.4.   Johnson & Johnson

13.5.   AstraZeneca plc

13.6.   Siemens Healthcare GmbH

13.7.   Quest Diagnostics Incorporated

13.8.   Thermo Fisher Scientific Inc

13.9.   Bio-Rad Technologies Inc

13.10. Eli Lily and Company

14. Strategic Recommendations

15. About Us & Disclaimer

Figures and Tables

Frequently asked questions


The market size of the United States Ovarian Cancer Diagnostics Market was estimated to be USD 284.13 million in 2023.


Abbott Laboratories Inc., F. Hoffmann-La Roche Ltd., GlaxoSmithKline plc, Johnson & Johnson, AstraZeneca plc., Siemens Healthcare GmbH, Quest Diagnostics Incorporated, Thermo Fisher Scientific Inc, Bio-Rad Technologies Inc, Eli Lily and Company. etc. were some of the key players operating in the United States Ovarian Cancer Diagnostics Market.


Asymptomatic Nature of Ovarian Cancer, High Cost of Diagnostic Tests are the challenges faced by the United States Ovarian Cancer Diagnostics Market in the upcoming years.


Growing Incidence and Prevalence of Ovarian Cancer, Advancements in Diagnostic Technologies, Increasing Awareness and Screening Initiatives are the major drivers for the United States Ovarian Cancer Diagnostics Market.


Sakshi Bajaal

Business Consultant
Press Release

United States Ovarian Cancer Diagnostics Market to Grow with a CAGR of 5.79% through 2029

Apr, 2024

Growing incidence and prevalence of ovarian cancer is expected to drive the United States Ovarian Cancer Diagnostics Market in the forecast period 2025-2029.